Developed a NMR displacement assay for fatty acid binding proteins, revealing binding affinity variations in metabolic diseases.
Fatty acid binding proteins play a pivotal role in lipid transport and signalling, with FABP4 emerging as a promising target for metabolic and inflammatory diseases. This work describes the development and validation of a ¹⁹F CPMG NMR displacement assay tailored for fragment screening and lead optimisation against FABP4. The method employs fluorinated spy molecules to quantify ligand binding through changes in transverse relaxation, offering a solution-phase, label-free alternative to conventional techniques. A focused screen validated the assay's broad affinity window and alignment with orthogonal data. The assay was benchmarked against ITC, SPR, and ¹⁵N-¹H HSQC, with good correlation across methods.
No takes yet. Share an insight, caveat, or question.
Konstantinidou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: